ANKE BIO(300009.SZ)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
ANKE BIO
300009.SZ
Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. It offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. The company provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, immunohistochemical, sperm DNA fragmentation staining, leptin, and immunohistochemical diagnostic kits.
1.484 T
300009.SZMarket value -Rank by Market Cap -/-

Financial Score

21/05/2026 Update
B
BiotechnologyIndustry
Industry Ranking11/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE15.72%A
    • Profit Margin27.11%A
    • Gross Margin75.59%A
  • Growth ScoreC
    • Revenue YoY2.02%C
    • Net Profit YoY-0.63%C
    • Total Assets YoY10.98%B
    • Net Assets YoY15.11%B
  • Cash ScoreC
    • Cash Flow Margin116.58%C
    • OCF YoY2.02%C
  • Operating ScoreC
    • Turnover0.48C
  • Debt ScoreA
    • Gearing Ratio13.42%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ANKE BIO: The "AK2017 Injection" is expected to initiate Phase III clinical trials in early next year

    Zhitong·
    SZ
    300009
    -0.60%
    Zhitong·
    SZ
    300009
    -0.60%

    ANKE BIO released its performance for the first three quarters, with a net profit attributable to the parent company of 551 million yuan, a decrease of 6.48%

    Zhitong·
    SZ
    300009
    -0.60%
    Zhitong·
    SZ
    300009
    -0.60%

    ANKE BIO simultaneously launches Phase III clinical trials for two new drugs for pediatric respiratory viral infections

    Zhitong·
    SZ
    300009
    -0.60%
    Zhitong·
    SZ
    300009
    -0.60%

    ANKE BIO: Innovative drug HuA21 injection will announce clinical research data at the 2025 European Society for Medical Oncology (ESMO) annual meeting

    Zhitong·
    SZ
    300009
    -0.60%
    Zhitong·
    SZ
    300009
    -0.60%

    ANKE BIO: The ORR of HuA21 injection combined with trastuzumab and chemotherapy for treating HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma reached 80.8%

    Zhitong·
    SZ
    300009
    -0.60%
    Zhitong·
    SZ
    300009
    -0.60%
    © 2026 Longbridge｜Disclaimer